A new study by Spano et al. has examined the relationship between EGFR expression, clinicohistological characteristics and survival in patients with colorectal cancer. Although EFGR was not shown ...

Investigations have shown that EGFR status is not predictive of success with anti-EGFR therapies in colorectal cancer. Scartozzi et al. studied EGFR status and expression of the EGFR downstream ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors.

But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer. According to Dr David Threadgill, adjunct professor in the department of genetics at ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer.

Please provide your email address to receive an email when new articles are posted on . Newer eGFR calculations that do not consider race show a link between kidney function and dementia.